Navigation Links
CuraGen Reports Second Quarter 2009 Financial Results
Date:7/31/2009

liability exposure; uncertainty of additional funding; CuraGen's history of incurring losses and the uncertainty of achieving profitability; reliance on research collaborations and strategic alliances; competition; patent infringement claims against CuraGen's products, processes and technologies; CuraGen's ability to protect its patents and proprietary rights; and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred in the section entitled "Risk Factors" in CuraGen's Annual Report on Form 10-K for the year ended December 31, 2008 and subsequent Quarterly Reports on Form 10-Q , in each case filed with the Securities and Exchange Commission, as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligation to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Additional Information About the Celldex-CuraGen Merger and Where to Find It

In connection with the proposed merger, Celldex and CuraGen intend to file relevant materials with the SEC, including a definitive joint proxy statement/prospectus (the "Joint Proxy Statement/Prospectus"). CuraGen and Celldex have already filed a preliminary joint proxy statement/prospectus with the SEC on June 26, 2009. This joint proxy statement/prospectus is only a preliminary version of the Joint Proxy Statement/Prospectus and should not be relied upon. INVESTORS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE BECAUSE
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
2. CuraGen Reports Third Quarter 2008 Financial Results
3. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
4. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
5. CuraGen to Present at the BIO CEO & Investor Conference
6. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
7. CuraGen Corporation Receives Notification from NASDAQ
8. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
9. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
10. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
11. CuraGen Appoints Clinical Oncologist as VP of Medical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... 2011  AMPAC Fine Chemicals LLC (AFC), ... announced it has concluded an agreement with Chimerix, Inc. ... the API in Chimerix,s broad spectrum antiviral drug candidate, ... treatment of smallpox.  Chimerix will provide the investigational drug ...
... Neurologix, Inc. (OTCBB: NRGX), a biotechnology company ... of the brain and central nervous system, today announced its ... 30, 2011. For the three months ended June ... million, as compared with a net loss of approximately $4.5 ...
... Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that ... Life Sciences Management Access Conference at the Le Parker Meridien ... presentation is scheduled for Wednesday, Aug. 17 at 3:35 p.m. ...   Interleukin,s management team will be available for ...
Cached Biology Technology:AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 2AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 3AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 4Neurologix Announces Second Quarter 2011 Financial Results 2Neurologix Announces Second Quarter 2011 Financial Results 3Neurologix Announces Second Quarter 2011 Financial Results 4Neurologix Announces Second Quarter 2011 Financial Results 5Neurologix Announces Second Quarter 2011 Financial Results 6Neurologix Announces Second Quarter 2011 Financial Results 7Neurologix Announces Second Quarter 2011 Financial Results 8Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference 2
(Date:7/10/2014)... cities in New Mexico, nearly every public golf course ... precious potable water supplies. Across the U.S. Southwest as ... receive treated effluent. Reusing the effluent increases the sustainability ... homeowners alike fertilize their lawns during the growing season. ... Mexico State University turfgrass expert has a new vision ...
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... the bugs. The rates of drug-resistant bacteria infecting patients ... increasing steadily in recent years, according to two new ... Diseases, now available online. , Drug resistance in microorganisms ... prescribing and overuse of antibiotics. These drug-resistant "superbugs" can ...
... a healthy dose of fat, suggests a new study published ... directly from the diet or generated from sugars spark a ... blood levels of sugar, cholesterol, and other fats, according to ... those critical metabolic pathways in motion, they found. The findings ...
... lung damage, according to a team of scientists who used ... in lung transplant patients. , Reporting in today's edition of ... University of Texas Medical School at Houston, and colleagues at ... than 1 percent of a certain type of reparative lung ...
Cached Biology News:Two studies document rise of superbugs in the environment 2Two studies document rise of superbugs in the environment 3Fat's fate depends on its source 2Circulating stem cells play small role in lung repair 2Circulating stem cells play small role in lung repair 3
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Phospho-MEF2A(Thr312)...
Tube-O-DIALYZER Floats, small....
Biology Products: